CD8A and neoplasm: Increased proportion of CD8+PD-1+ T-cells normalized to tumor cell count was prognostic for improved survival with a median OS of 47 vs 20 months (high vs low, HR 0.678; 0.468–0.981; p = 0.039; Fig. 2).